A new observational analysis examined cardiovascular outcomes recorded in US administrative claims among adults with type 2 diabetes and atherosclerotic cardiovascular disease. The study compared people who newly initiated oral Semaglutide with users of other noninsulin glucose-lowering therapies. Its central finding was an association, not proof of cause and effect: the authors reported lower event rates across several cardiovascular outcome definitions in the oral Semaglutide groups.
The study used Optum’s deidentified Clinformatics Data Mart Database. It compared new users with broader other-therapy users and, in separate propensity score-matched analyses, with new users of DPP-4 inhibitors or SGLT2 inhibitors. Administrative claims can make large, real-world comparisons possible, but they do not randomly assign exposures. That distinction is essential when reading the reported percentages.
What the claims analysis compared
The authors identified 10,878 oral Semaglutide users and 28,639 users of other noninsulin glucose-lowering therapies in the broader comparison. They also reported two matched comparisons: 7,218 oral Semaglutide initiators matched to 7,218 DPP-4 inhibitor initiators, and 7,491 oral Semaglutide initiators compared with 21,572 SGLT2 inhibitor users.
The endpoints included three-point and modified three-point major adverse cardiovascular events, along with broader composite outcomes, ischaemic stroke, myocardial infarction, all-cause death and cardiovascular-related death. The paper’s method is therefore a comparison of coded outcome rates after matching, rather than a randomised test of a defined intervention under a common protocol.
The associations the authors reported
Against the broader other-therapy group, the authors reported 17% and 21% lower risks for three-point and modified three-point major adverse cardiovascular events. In the DPP-4 inhibitor comparison, the corresponding reported reductions were 22% and 24%. Against SGLT2 inhibitor users, the reported figures were 21% and 22%.
The authors also reported statistically significant differences for several broader composite endpoints, ischaemic stroke and all-cause death in the comparisons described in the abstract. These figures should be read as modelled associations in a retrospective database, not as a measure of what will occur for any individual or in a different health system.
Why the design limits the conclusion
Propensity score matching can make measured baseline characteristics more comparable between groups. It cannot account for every difference that was not measured, was incompletely coded, or changed during follow-up. Claims data also record billing and diagnostic codes rather than a trial team’s standardised research assessments.
For that reason, the analysis can support a research question about whether its pattern is consistent across settings. It cannot by itself establish that oral Semaglutide caused the observed differences, determine why they occurred, or replace a randomised comparison. The abstract also identifies conflicts of interest: six authors were employees of Novo Nordisk, and another author reported several financial relationships. Those disclosures do not invalidate the results, but they are part of the study context.
How this fits with the existing evidence
The authors frame the work against earlier cardiovascular trial evidence for semaglutide. That background does not turn this cohort into a trial. The value of the new paper is its specific real-world question: whether associations are visible among new oral users with both type 2 diabetes and established atherosclerotic cardiovascular disease in an administrative database.
The publication does not compare Semaglutide with Retatrutide or Tirzepatide, and neither material was part of the cohort. They should not be inferred to have the outcomes reported here. For separate research context, see the Retatrutide research buyer guide and Retatrutide research reference hub.
Peptra Labs materials sit within a Research Use Only boundary. This article reports a published database analysis and is not a protocol or instruction for human use.
The measured takeaway is narrow: in this claims cohort, the authors found lower coded cardiovascular outcome rates among new oral Semaglutide users than among the comparison groups. Prospective, protocol-defined research remains necessary to test causal explanations for those associations.
References
- Tan X, Liang Y, Zhong C, et al. Comparing cardiovascular outcomes in new users of oral semaglutide versus other noninsulin glucose-lowering therapies among adults with type 2 diabetes and atherosclerotic cardiovascular disease. Diabetes Therapy. 2026. PubMed
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019. Article
- von Elm E, Altman DG, Egger M, et al. The STROBE statement. PLoS Medicine. 2007. Article
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
